FDA approves Idorsia’s high blood pressure drug for patients who need other options
The FDA on Tuesday approved Idorsia’s new treatment for patients with high blood pressure who aren’t adequately treated by current medications. But the drug comes with a black box safety warning and will only be available through a restricted program due to the risk of embryo-fetal toxicity.
The approval for aprocitentan, which has been branded as Tryvio, comes after Johnson & Johnson backed away from its partnership on the drug last year, but the Big Pharma will still get royalties on sales of the drug and 30% of proceeds from any out-licensing deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
